Aclaris (ACRS) director Andrew Schiff reports RSU vesting and new stock option grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Aclaris Therapeutics director Andrew N. Schiff reported routine equity compensation and an RSU vesting and conversion. On June 5, 2026, 11,580 restricted stock units vested and were converted into 11,580 shares of common stock, bringing his directly held common shares to 25,540.
On June 4, 2026, he received 10,987 new restricted stock units and a stock option for 42,350 shares at an exercise price of $4.71 per share, both granted under company equity plans. The option vests in twelve equal monthly installments starting July 4, 2026, and the new RSUs vest on June 4, 2027, subject to continuous service.
A separate indirect position of 434,455 common shares is held by Aisling Capital IV LP and related entities, over which Aisling GP, Aisling Partners, and their managers share voting and dispositive power. Dr. Schiff disclaims beneficial ownership of these Aisling-held shares except to the extent of his pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
11,580 shares exercised/converted
Mixed
5 txns
Insider
SCHIFF ANDREW N
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 11,580 | $0.00 | -- |
| Exercise | Common Stock | 11,580 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 42,350 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 10,987 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 0 shares (Direct, null);
Common Stock — 25,540 shares (Direct, null);
Stock Option (Right to Buy) — 42,350 shares (Direct, null);
Common Stock — 434,455 shares (Indirect, By Aisling Capital IV LP)
Footnotes (1)
- Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. The shares underlying these restricted stock units vested on June 5, 2026.
Key Figures
RSUs converted to common: 11,580 shares
Direct common shares after conversion: 25,540 shares
New RSU grant: 10,987 units
+4 more
7 metrics
RSUs converted to common
11,580 shares
Restricted stock units vested and converted on June 5, 2026
Direct common shares after conversion
25,540 shares
Common stock directly held following June 5, 2026 transaction
New RSU grant
10,987 units
Restricted stock unit award on June 4, 2026
New stock option grant
42,350 options
Stock option for common shares granted on June 4, 2026
Stock option exercise price
$4.71 per share
Exercise price for 42,350-share stock option grant
Indirect Aisling-held shares
434,455 shares
Aclaris common stock held by Aisling Capital IV LP and affiliates
Option expiration date
June 3, 2036
Expiration of 42,350-share stock option grant
Key Terms
restricted stock unit, stock option, continuous service, beneficial ownership, +2 more
6 terms
restricted stock unit financial
"Each restricted stock unit represents a contingent right to receive one share of common stock"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
stock option financial
"The shares subject to this stock option will vest in twelve equal monthly installments"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
continuous service financial
"subject to the Reporting Person's Continuous Service as defined in the Issuer's 2025 Equity Incentive Plan"
beneficial ownership financial
"Dr. Schiff disclaims beneficial ownership of these securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
voting and dispositive power financial
"share voting and dispositive power over the shares directly held by Aisling"
non-employee director compensation policy financial
"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy"
FAQ
What equity awards did Aclaris (ACRS) director Andrew Schiff receive in this Form 4?
Andrew Schiff received 10,987 restricted stock units and a stock option for 42,350 shares at an exercise price of $4.71 per share, granted under Aclaris equity plans as non-employee director compensation.
What happened to Andrew Schiff’s existing Aclaris (ACRS) restricted stock units?
On June 5, 2026, 11,580 restricted stock units vested and converted into 11,580 Aclaris common shares. Following this RSU conversion, Schiff directly held 25,540 shares of Aclaris common stock, reflecting the newly issued shares from the vesting event.
How and when do Andrew Schiff’s new Aclaris (ACRS) stock options vest?
The 42,350-share stock option vests in twelve equal monthly installments starting July 4, 2026. Vesting continues monthly as long as Andrew Schiff remains in continuous service under Aclaris’s 2025 Equity Incentive Plan until the grant is fully vested.
When do Andrew Schiff’s new Aclaris (ACRS) restricted stock units vest?
The 10,987 new restricted stock units will vest in a single installment on June 4, 2027, provided Andrew Schiff remains in continuous service as defined in Aclaris’s 2025 Equity Incentive Plan at that vesting date.
What indirect Aclaris (ACRS) holdings are reported through Aisling Capital entities?
The filing reports 434,455 Aclaris common shares owned directly by Aisling Capital IV LP and held indirectly through Aisling GP and Aisling Partners. These entities and their managers share voting and dispositive power over the shares held by Aisling.